Form 4 for PFE Pfizer
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0001225208-24-003056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-27 | 2024-02-23+ | PFE | McDermott Michael | EVP | F - Tax | $27.39 | -19.9K | 94.5K | -17% | -$546.2K |
| D | 2024-02-27 | 2024-02-23 | PFE | McDermott Michael | EVP | M - OptEx | $27.34 | +12.4K | 95.4K | +15% | +$339.3K |
| D | 2024-02-27 | 2024-02-23 | PFE | McDermott Michael | EVP | M - OptEx | $0.00 | -12.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-26 | F | D | 6,063 | $27.18 | 75,463 | D | — | — | (F5) The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). |
| 2 | Common | Common Stock | 2024-02-23 | M | A | 12,412 | $27.34 | 95,408 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 3 | Common | Common Stock | 2024-02-25 | F | D | 2,992 | $27.76 | 81,526 | D | — | — | (F5) The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). (F6) Price is the closing price of Pfizer common stock on February 23, 2024. |
| 4 | Common | Common Stock | 2024-02-23 | F | D | 10,031 | $27.37 | 84,518 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 5 | Common | Common Stock | 2024-02-23 | F | D | 859 | $27.76 | 94,549 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 6 | Derivative | Stock Appreciation Rights | 2024-02-23 | M | D | 12,412 | $0.00 | 0 | D | $27.34 · 2024-02-23 to 2024-02-23 | 12,412 Common Stock | (F7) The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |